Author

David Hall

Observed name: Hall, David B

Institution: Boehringer Ingelheim (United States)

Observed institution: Boehringer Ingelheim (United States)

OpenAlex ID: A5114021303

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

2015 · James G. Krueger, Laura K. Ferris, et al. · Journal of Allergy and Clinical Immunology · 265

812a Efficacy and Safety of Induction Therapy With the Selective IL-23 Inhibitor BI 655066, in Patients With Moderate-to-Severe Crohn's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study

2016 · Brian G. Feagan, William Sandborn, et al. · Gastroenterology · 14

A mouse model for studying rapid intraoperative methods of skin closure and wound healing.

2003 · Xi Zhu, David Hall, et al. · PubMed · 8

Efficacy and Safety of Open-Label Maintenance Therapy with Subcutaneous Risankizumab in Patients with Moderateto-Severe Crohn's Disease

2017 · Brian G. Feagan, Julian Panes, et al. · Gastroenterology · 4

Spesolimab Treatment for People with Flares of Generalized Pustular Psoriasis: A Plain Language Summary of the Effisayil™ 1 Study

2022 · Siew Eng Choon, Slaheddine Marrakchi, et al. · Future Rare Diseases

Works count: 6

Citation count: 291

H-index: 4

I10-index: 2